Palmitoylethanolamide (Pea) for Fibromyalgia

Research suggests that palmitoylethanolamide (PEA), typically studied in combination with acetyl-L-carnitine rather than as a standalone supplement, may offer meaningful symptom relief for fibromyalgia when added to standard pharmacological treatment, with two controlled studies and one observational study all reporting improvements in pain and overall disease impact scores compared to standard care alone. The available evidence base includes one randomized controlled trial, one retrospective matched cohort study, and one observational study, all of which point in a supportive direction, though the designs carry meaningful limitations including small sample sizes, lack of placebo controls in some cases, and the inability to isolate PEA's effects from those of co-administered supplements. Adding complexity to the picture, two separate blood-level studies found that PEA is naturally elevated in women with fibromyalgia and chronic widespread pain compared to healthy controls, a finding whose implications remain unclear and which the study authors themselves describe as insufficient to draw firm clinical conclusions. A longer-term observational follow-up also found that only a minority of patients showed substantial improvement over 24 months and that psychological factors significantly influenced outcomes, underscoring that the overall evidence, while cautiously encouraging, remains preliminary and that well-designed, placebo-controlled trials isolating PEA's specific contribution are still needed.